SubMagna HMW

11/25/2025

Curious what everyone’s talking about with SubMagna® HMW and sublingual compounding? 👀

If you’re a pharmacist or prescriber and want to dig in, start here:

PCCA

11/25/2025

There’s a new addition inside the SubMagna® HMW portfolio.

At the request of healthcare providers, some pharmacies are now preparing compounded Suzetrigine in SubMagna® HMW, bringing this permeation-enhancing, self-emulsifying sublingual base to another emerging therapeutic category. It's simple - grind up the commercially available Suzetrigine tablet, add flavoring and SubMagna® HMW and you're there.

As always, SubMagna® HMW supports formulators who need:

• A stable, anhydrous suspension platform
• Rapid self-emulsification on contact with saliva
• Enhanced mucosal contact time
• Improved wetting and dispersibility for low-solubility APIs

This new formula reflects exactly what SubMagna® was built for - expanding the range of actives that can be explored via the sublingual route.

If your pharmacy is interested in incorporating advanced sublingual formulations into your workflow, visit www.SubMagna.com.

Compounded medications are not reviewed by the FDA for safety or efficacy. Formulations using SubMagna® HMW must be prepared by licensed compounding pharmacies in accordance with all state and federal regulations.

PCCA Kingdom Investment Holdings

JOURNAVX is an oral nonopioid indicated for the treatment of moderate-to-severe acute pain in adults—the first and only oral pain signal inhibitor highly selective for NaV1.81

11/10/2025

With new agreements from President Donald Trump promising lower prices on popular weight-loss drugs, the use of GLP-1 medications such as Ozempic and Mounjaro could soon surge even higher.

10/22/2025

https://www.independent.co.uk/news/world/americas/wegovy-weight-loss-injections-states-cost-b2849330.html

At least four states are trying to slash weight loss drug coverage

10/19/2025

🌍 From Texas to Tokyo - SubMagna® HMW is changing how the world compounds.

Any pharmacy, anywhere in the world, can use SubMagna® HMW - and frankly, everyone should. Every prescriber should DEMAND SubMagna® HMW be a part a compounded prescribed sublingual.

This innovative sublingual delivery base helps eliminate needles and improves sublingual delivery of Semaglutide, Sermorelin, NAD+ and so much more.

Innovation doesn’t have borders. Neither should better medicine.
👉 Learn more at www.SubMagna.com

Compounded medications are not reviewed by FDA for safety or efficacy.

Shark Tank Flamingo Charger Kingdom Investment Holdings Richie's Specialty Pharmacy PCCA RISE Institute for Compounding

10/12/2025

Where innovation meets impact. 💡❤️

At PCCA International 2025, SubMagna® HMW proudly stood alongside Smith Baggett, owner of Flamingo Charger (yes - the Shark Tank legend himself), and our friends at Bassagel, spotlighting how compounding innovation can fuel global philanthropy.

💥 Every share of this post on Facebook = $50 donated to the RISE Institute for Compounding, up to $50,000 total through October 15, 2025.

Together, we’re advancing patient care, empowering compounding pharmacies worldwide, and giving back to the profession that gives so much.

Let’s prove that innovation isn’t just about better medicine - it’s about better impact. 🌍

👉 Share this post.
👉 Tag your peers.
👉 Be part of the movement.



https://www.riseinstituteforcompounding.org/

09/27/2025

💡 GLP-1 medications are doing more than weight loss. They help with blood sugar, heart health, and may even reduce inflammation. Early research shows potential benefits in lupus and lupus nephritis - check out the article referenced!

For those wanting a needle-free option, some pharmacies offer compounded sublingual Semaglutide in SubMagna® HMW — simple and convenient under-the-tongue dosing.

👉 Learn more at www.subsema.com
| www.submagna.com

Compounded medications are not reviewed by FDA for safety or efficacy.



https://www.medpagetoday.com/rheumatology/lupus/117674?xid

It's getting harder to argue against these products as wonder drugs

09/23/2025

💡 Have Psoriasis?

GLP-1 medications like Semaglutide aren’t just about weight loss.

✨ New research shows they may also help with skin conditions such as psoriasis.

Pharmacies worldwide are compounding Semaglutide in SubMagna® HMW — a simple, needle-free sublingual option that makes access easier and more affordable.

👉 Learn more: www.SubSema.com and| www.SubMagna.com

⚠️ Compounded medications are not reviewed by the FDA for safety or efficacy.

Psoriasis is associated with cardiometabolic and psychiatric comorbidity. The anti-obesity and anti-diabetes glucagon-like peptide-1 receptor agonists (GLP

09/16/2025

Why might a compounded semaglutide dose look higher?

A weekly 7.2 mg subcutaneous dose (≈ 89% bioavailability) equates to ~6.4 mg absorbed. Assuming ~10% compounded sublingual absorption in SubMagna® HMW, an estimated 9.15 mg daily dose is needed to reach similar exposure. The latter is focused on estimates related to compounded drug products containing Semaglutide in SubMagna® HMW.

📌 Learn more: www.subsema.com and www.submagna.com

⚠️ Compounded medications are not FDA-reviewed for safety or efficacy. Sublingual absorption estimates are just that - estimates.

PCCA

Semaglutide 7·2 mg was superior to placebo and 2·4 mg for bodyweight reduction in adults with obesity, while retaining a favourable risk–benefit profile.

09/13/2025

SubMagna® HMW is a core / integral part of the referenced approach embraced by Richie's Specialty Pharmacy and pharmacies worldwide related to compounded sublingual delivery of drugs such as GLP-1s. Reach out to Richie's Specialty Pharmacy via richie@richiespharmacy.com. They're happy to share with you the approach they're doing and what they are seeing in patients.

PCCA

The FDA does not review any compounded medication for safety or efficacy. Richie’s Specialty Pharmacy® (“RSP”) is a registered trademark of Richie’s Pharmacy and Medical Supply, LLC. RSP serves patients solely within the state of Texas. No compounded medication is reviewed by FDA for safety...

09/08/2025

08/25/2025

🧪 Cannabis Delivery Innovation in Europe

As research into cannabis compounds and healthy aging gains momentum, European healthcare providers are investigating how SubMagna® HMW could be useful in compounded sublingual cannabinoid administration.

Why it matters: SubMagna® HMW's unique absorption profile could offer precision dosing, enhanced bioavailability, and non-invasive delivery for therapeutic cannabis applications.

📍 From pain management to neuroprotection, this could reshape how we think about formulation strategy and patient access.



Compounded medications are not reviewed by FDA for safety or efficacy.

Cannabis compounds are showing early promise for healthy aging, a new study has found. However, much more research is needed to learn how results might differ depending on the frequency of use and the individual. Researchers in the UK reviewed 18 different studies across 15 years of research (2008 t...